About EAM
About EAM
The European Academy of Medical Sciences unites global top medical scientists for interdisciplinary research and innovation.
EAM Overview
Governance
Our Impact

Collaboration

Code of Conduct
EAM News
EAM News
Stay informed with the latest updates and breakthroughs from the European Academy of Medical Sciences.
EAM Sections
EAM Sections
Explore specialized divisions within the European Academy of Medical Sciences advancing global medical research.
EAM Community
EAM Community
Connect with a global network of esteemed medical professionals and researchers in the EAM community.
Student Member
Apprentice Member
EAM Scholar
Professorship
Fellow (FEAM)
Life Fellow (LFEAM)
The Directory of Life Fellows
Verification of Membership Credentials
Medals and Awards
Medals and Awards
Recognizing excellence in medical science through prestigious medals and awards from the European Academy of Medical Sciences.
Medals and Awards
European Lifetime Achievement Award in Medical Sciences European Innovation in Medicine Award European Outstanding Medical Scientist Award European Clinical Excellence Award European Medical Impact Award European Distinguished Medicine Educator Award
Past Winner Cohorts
2024 Winners 2023 Winners 2022 Winners
Joint R&D
Joint R&D
Facilitating collaborative research and development with global health and pharmaceutical leaders through EAM's expert network.
EAM Accreditation
Medals
EAM Accreditation ensures the highest standards of excellence in medical science and healthcare practices worldwide.
Policy
Policy
EAM Policy outlines our commitment to ethical standards, scientific integrity, and global healthcare leadership.

Professor

Jane Osbourn

CSO Alchemab Therapeutics

Alchemab Therapeutics

United Kingdom

Year elected: 2020

Types of Fellowship

Life Fellow

Areas of expertise

Antibody engineering, immunology, biologics drug discovery and development

BIO

Jane Osbourn is CSO of Alchemab Therapeutics and her contribution to medical sciences has been to generate antibody-based medicines in the Biotech and Pharma industry. She contributed to the discovery and development of 8 approved drugs with all the subsequent benefits to human health. Her work at Cambridge Antibody Technologies contributed to the invention of Humira, Benlysta and Abthrax before becoming a key member of the MedImmune team that delivered Durvalumab, Moxetumumab, Broadalumab, Benralizumab and influenza vaccines to the market. She continues to pioneer new antibody-based medicines and is the scientific founder of a biotech company taking an entirely novel approach to find naturally-occurring protective antibodies and developing them as therapeutics.